Icosavax Raises $100m To Take RSV, COVID-19 Vaccines Into The Clinic

Platform Enables Vaccines Based On Non-Naturally Occurring VLPs

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company doubled its series A total of $51m to not only test its coronavirus and RSV candidates, but to also advance a vaccine targeting both RSV and hMPV for pneumonia prevention in elderly adults.

Vaccine vial dose
Icosavax's first vaccines aim to prevent COVID-19 and pneumonia • Source: Shutterstock

Icosavax, Inc. advanced its virus-like particle (VLP) technology platform for the creation of novel vaccines that prevent respiratory diseases and scaled up manufacturing to support clinical trials with $51m in series A venture capital it raised in 2019. The company also developed a candidate for the prevention of COVID-19, which received $16.5m in early funding commitments late last year, and now it has raised a $100m series B round to take its vaccine against SARS-CoV-2 and its other lead vaccine candidate for respiratory syncytial virus (RSV) into clinical trials in 2021.

Seattle-based Icosavax, which announced its new funding on 7 April, launched in October 2019 to develop vaccines based on computationally...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.